LT2285408T - Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui - Google Patents

Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui

Info

Publication number
LT2285408T
LT2285408T LTEP09757629.2T LT09757629T LT2285408T LT 2285408 T LT2285408 T LT 2285408T LT 09757629 T LT09757629 T LT 09757629T LT 2285408 T LT2285408 T LT 2285408T
Authority
LT
Lithuania
Prior art keywords
polypeptides
virus
treatment
amino acid
acid sequences
Prior art date
Application number
LTEP09757629.2T
Other languages
English (en)
Inventor
Anna Hultberg
Bram Maassen
Peter Vanlandschoot
Erik Depla
Catelijne Stortelers
Cornelis Theodorus Verrips
Steven Van Gucht
Jose Melero
Michael John Scott Saunders
Johannes Joseph Wilhelmus De Haard
Robert Anthony Weiss
Nigel James Temperton
Xavier Saelens
Bert Schepens
Alexander Szyroki
Michael Marie Harmsen
Original Assignee
Ablynx N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx N.V. filed Critical Ablynx N.V.
Publication of LT2285408T publication Critical patent/LT2285408T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/106—Picornaviridae (F), e.g. hepatitis A virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEP09757629.2T 2008-06-05 2009-06-05 Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui LT2285408T (lt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US5905508P 2008-06-05 2008-06-05
US9299108P 2008-08-29 2008-08-29
US13913008P 2008-12-19 2008-12-19
US14465309P 2009-01-14 2009-01-14
US17291409P 2009-04-27 2009-04-27
US17410809P 2009-04-30 2009-04-30
PCT/EP2009/056975 WO2009147248A2 (en) 2008-06-05 2009-06-05 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases

Publications (1)

Publication Number Publication Date
LT2285408T true LT2285408T (lt) 2019-01-25

Family

ID=41055279

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP09757629.2T LT2285408T (lt) 2008-06-05 2009-06-05 Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui

Country Status (17)

Country Link
US (4) US9193780B2 (lt)
EP (2) EP2285408B1 (lt)
JP (2) JP5809557B2 (lt)
CN (1) CN102112155B (lt)
AU (1) AU2009254501B2 (lt)
CA (1) CA2726652A1 (lt)
CY (1) CY1121687T1 (lt)
DK (1) DK2285408T3 (lt)
ES (1) ES2713864T3 (lt)
HR (1) HRP20182195T1 (lt)
HU (1) HUE042053T2 (lt)
LT (1) LT2285408T (lt)
PL (1) PL2285408T3 (lt)
PT (1) PT2285408T (lt)
SI (1) SI2285408T1 (lt)
WO (1) WO2009147248A2 (lt)
ZA (1) ZA201009135B (lt)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
AU2009254501B2 (en) 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
US8858940B2 (en) 2008-12-10 2014-10-14 Ablynx N.V. Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
ES2643034T3 (es) * 2009-06-05 2017-11-21 Ablynx N.V. Construcciones de Nanobody contra el virus respiratorio sincicial humano (VRSH) trivalentes para la prevención y/o el tratamiento de infecciones de las vías respiratorias
AU2015200057B9 (en) * 2009-06-05 2017-03-09 Ablynx Nv Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hRSV) Nanobody constructs for the prevention and/or treatment of respiratory tract infections
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
PT3501499T (pt) 2010-02-11 2022-11-22 Ablynx Nv Métodos e composições para a preparação de aerossóis
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
WO2012088290A2 (en) * 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
IN2014CN00437A (lt) 2011-06-23 2015-04-03 Ablynx Nv
DK2723769T4 (da) 2011-06-23 2022-09-05 Ablynx Nv Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner
CN106046168A (zh) 2011-06-23 2016-10-26 埃博灵克斯股份有限公司 结合血清白蛋白的蛋白
CN104114186B (zh) * 2011-08-03 2017-05-03 儿童医疗中心有限公司 识别流行性感冒血凝素的受体‑结合袋状结构的广泛中和人类抗体
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
AU2013226340B2 (en) 2012-02-27 2017-06-22 Ablynx N.V. CX3CR1-binding polypeptides
TR201908638T4 (tr) * 2012-03-30 2019-07-22 Boehringer Ingelheim Int Ang2 bağlayıcı moleküller.
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
EP2970397A2 (en) 2013-03-14 2016-01-20 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
WO2014140358A1 (en) * 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Single chain binding molecules comprising n-terminal abp
AR095774A1 (es) * 2013-04-05 2015-11-11 Genentech Inc Anticuerpos anti-il-4 y anticuerpos biespecíficos y sus usos
WO2015026884A1 (en) * 2013-08-21 2015-02-26 Boehringer Ingelheim International Gmbh Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease
EP3074423A1 (en) * 2013-11-25 2016-10-05 Oxford BioTherapeutics Ltd Antibodies anti matriptase for the treatment of cancer
RU2017115670A (ru) * 2014-10-10 2018-11-15 Аблинкс Н.В. Лечение инфекции рсв
US11001625B2 (en) 2014-12-10 2021-05-11 Tufts University VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス，インコーポレイティド 非免疫原性単一ドメイン抗体
EA038407B1 (ru) * 2015-02-05 2021-08-24 Янссен Вэксинс Энд Превеншн Б.В. Связывающие молекулы, направленные против гемагглютинина вируса гриппа, и пути их применения
EP3271391A1 (en) * 2015-03-20 2018-01-24 Ablynx N.V. Glycosylated immunoglobulin single variable domains
HK1250011A1 (zh) 2015-03-31 2018-11-23 Sorriso Pharmaceuticals, Inc. 具有蛋白酶可切割接头的肽构建体
WO2016156475A1 (en) * 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b
DK3277719T3 (da) 2015-03-31 2022-05-02 Sorriso Pharmaceuticals Inc Polypeptider
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
EA201792573A1 (ru) 2015-05-21 2018-04-30 Харпун Терапьютикс, Инк. Триспецифические связанные белки и способы их применения
CA2989378A1 (en) 2015-06-18 2016-12-22 Vib Vzw Immunoglobulin single variable domain antibody against rsv prefusion f protein
EP3124042A1 (en) 2015-07-28 2017-02-01 VIB, vzw Immunoglobulin single variable domain antibody against rsv prefusion f protein
NZ777930A (en) 2015-07-16 2025-05-02 Inhibrx Biosciences Inc Multivalent and multispecific dr5-binding fusion proteins
JP2017036258A (ja) * 2015-08-07 2017-02-16 パナソニックＩｐマネジメント株式会社 インフルエンザウィルスに結合する抗体
US10538557B2 (en) * 2015-09-02 2020-01-21 Janssen Vaccines & Prevention B.V. Stabilized viral class I fusion proteins
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN116987189A (zh) 2016-05-20 2023-11-03 哈普恩治疗公司 单链可变片段cd3结合蛋白质
EP3544629A4 (en) 2016-11-23 2020-06-17 Harpoon Therapeutics, Inc. PSMA TO BE TRISPECIFIC PROTEINS AND METHOD FOR USE THEREOF
CN110198955A (zh) 2016-11-23 2019-09-03 哈普恩治疗公司 前列腺特异性膜抗原结合蛋白质
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
WO2018209304A1 (en) * 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
JP7189211B2 (ja) * 2017-10-11 2022-12-13 ナンジン レジェンド バイオテック カンパニー，リミテッド 血清中のタンパク質の半減期を増加させるための組成物及び方法
HRP20241268T1 (hr) 2017-10-13 2024-12-06 Harpoon Therapeutics, Inc. Trispecifični proteini i postupci primjene
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
US12071632B2 (en) * 2018-04-23 2024-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric vectors
KR20210020903A (ko) 2018-05-14 2021-02-24 하푼 테라퓨틱스, 인크. 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
CN108794626B (zh) * 2018-06-18 2021-10-12 上海大学 一种多肽以及能靶向HIV包膜蛋白gp120的金纳米抗体
CN108640978A (zh) * 2018-06-20 2018-10-12 上海大学 特异性结合HIV病毒上蛋白gp120的多肽及其应用
CN110317267B (zh) * 2018-08-09 2020-11-20 北京智仁美博生物科技有限公司 针对狂犬病病毒的双特异性抗体及其用途
JP7190675B2 (ja) 2018-08-23 2022-12-16 パナソニックＩｐマネジメント株式会社 ノロウイルスに結合する抗体、複合体、それを用いた検出装置及び検出方法
JP7190674B2 (ja) 2018-08-23 2022-12-16 パナソニックＩｐマネジメント株式会社 ノロウイルスに結合する抗体、複合体、それを用いた検出装置及び検出方法
CN109097341B (zh) * 2018-08-28 2021-09-24 青岛农业大学 一种同时表达ha和hef的复制缺陷型重组流感病毒
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
SG11202103022WA (en) 2018-09-25 2021-04-29 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
AU2019364823B2 (en) 2018-10-25 2025-10-30 Km Biologics Co., Ltd. Modified CMV gB protein and CMV vaccine including same
CN113490686B (zh) 2019-01-07 2025-02-18 拜科托莱夫股份有限公司 病原体结合蛋白
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
US12516128B2 (en) 2019-05-14 2026-01-06 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
JP7680377B2 (ja) 2019-06-21 2025-05-20 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
KR20220063148A (ko) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. 조성물
WO2020254827A1 (en) 2019-06-21 2020-12-24 Vhsquared Limited Polypeptides
CA3166967A1 (en) * 2020-02-06 2021-08-12 Bert Schepens Corona virus binders
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
CN111393512B (zh) * 2020-03-24 2021-03-02 北京中科微盾生物科技有限责任公司 一种抑制流感病毒的多肽及其在制备预防和治疗流感病毒感染药物中的应用
EP4130041A4 (en) * 2020-03-31 2024-05-22 Biotheus Inc. ANTI-PD-L1 AND PD-L2 ANTIBODIES AND DERIVATIVES AND USE THEREOF
US20230220054A1 (en) * 2020-04-20 2023-07-13 Ab Studio Inc. Anti-coronavirus antibodies and uses thereof
US20210330700A1 (en) * 2020-04-23 2021-10-28 Johnson & Johnson Consumer Inc. Methods and compositions for inhibiting influenza viruses using low molecular weight hydrophobically modified polymers and polyalkylene glycols
AU2021271016A1 (en) * 2020-05-12 2023-01-19 The Regents Of The University Of California SARS-CoV2 neutralizing single domain antibody constructs
WO2022006219A2 (en) 2020-07-02 2022-01-06 Trustees Of Tufts College Vhh polypeptides that bind to clostridium difficile toxin b and methods of use thereof
EP4200329A4 (en) * 2020-08-19 2025-01-22 University of Pittsburgh - of the Commonwealth System of Higher Education CORONAVIRUS NANOBODIES AND METHODS OF USE AND IDENTIFICATION THEREOF
TWI829014B (zh) * 2020-09-29 2024-01-11 中央研究院 Clec2融合蛋白及其用途
US20240109963A1 (en) * 2020-11-16 2024-04-04 Ab Therapeutics, Inc. Multispecific antibodies and uses thereof
CN112851811B (zh) * 2021-01-28 2022-08-09 姜国胜 一种cd44v6纳米抗体及其作为白血病研究试剂的应用
JP2022165899A (ja) * 2021-04-20 2022-11-01 株式会社デンソー 融合体
CN113234151B (zh) * 2021-06-08 2022-02-15 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种基于靶向SARS-CoV2病毒S蛋白的三聚体纳米抗体的CAR-NK的研制
US11970548B2 (en) * 2021-08-27 2024-04-30 Innovative Cellular Therapeutics Holdings, Ltd. Nanobody target GCC and uses in chimeric antigen receptor cell therapy
WO2023039528A1 (en) * 2021-09-10 2023-03-16 The Board Of Trustees Of The Leland Stanford Junior University Nanobody-mediated control of gene expression and epigenetic memory
WO2023177821A2 (en) * 2022-03-16 2023-09-21 Myeloid Therapeutics, Inc. Binding domains and methods of use thereof
WO2024068744A1 (en) * 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
AR131494A1 (es) 2022-12-23 2025-03-26 Ablynx Nv Vehículos de conjugación a base de proteína
JP2026506075A (ja) 2023-02-17 2026-02-20 アブリンクス エン．ヴェー． 新生児型ｆｃ受容体に結合するポリペプチド
CN116375852B (zh) * 2023-03-10 2024-02-02 华南农业大学 重组荧光纳米抗体及其在制备狂犬病病毒检测试剂中的应用
CN116751284B (zh) * 2023-06-13 2024-06-04 康元医疗科技(大连)有限公司 一种纳米抗体、包含该纳米抗体的多肽及其应用
WO2024259305A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
CN116987194B (zh) * 2023-09-26 2023-12-26 江西乐成欣生生物技术研究有限责任公司 人st2抗原的模拟表位肽的抗独特型纳米抗体及应用
CN117683137B (zh) * 2023-12-04 2024-09-17 江苏省农业科学院 靶向新城疫病毒和h9亚型禽流感病毒的重组双特异性纳米抗体及其制备方法和应用
TW202543670A (zh) 2023-12-22 2025-11-16 比利時商艾伯霖克斯公司 用於核內投予之基於蛋白質的接合載劑
CN117843801B (zh) * 2023-12-29 2024-08-02 北京贝来药业有限公司 以白介素家族成员为靶点的新型抗体以及下游产品
CN117986360B (zh) * 2024-02-01 2024-08-27 生物岛实验室 Il18蛋白的特异性抗体及其制备方法与应用
US20260007757A1 (en) 2024-06-18 2026-01-08 Ablynx Nv Antibody-recruiting molecules
WO2026060159A1 (en) * 2024-09-13 2026-03-19 Gilead Sciences, Inc. Vhhs against hsv and uses of the same
WO2026076388A1 (en) 2024-10-03 2026-04-09 The Broad Institute, Inc. Vhh polypeptides that bind to claudin-18, compositions and methods of use thereof
CN119978135B (zh) * 2025-01-02 2025-11-21 生物岛实验室 Sumo标签蛋白的特异性抗体及其制备方法与应用
CN120623329B (zh) * 2025-01-15 2026-04-10 中国人民解放军军事科学院军事医学研究院 抗埃博拉病毒vp40蛋白的纳米抗体3e07及在病毒检测中的应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1120945A (en) 1964-08-11 1968-07-24 Fisons Pharmaceuticals Ltd Applicator in combination with a pressurised aerosol dispensing container
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
EP0542810A1 (en) 1990-08-02 1993-05-26 B.R. Centre Limited Methods for the production of proteins with a desired function
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
AU675223B2 (en) 1992-05-08 1997-01-30 Creative Biomolecules, Inc. Chimeric multivalent protein analogues and methods of use thereof
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6020182A (en) 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
CA2270288A1 (en) 1996-11-01 1998-05-14 Smithkline Beecham Corporation Human monoclonal antibodies
US7122636B1 (en) * 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
DE60013767T3 (de) 1999-01-19 2009-07-09 Unilever N.V. Verfahren zur herstellung von antikörperfragmenten
CN1252264C (zh) * 1999-04-22 2006-04-19 荷兰联合利华有限公司 利用单价抗原－结合蛋白抑制病毒感染
US6133571A (en) * 1999-04-26 2000-10-17 Lockheed Martin Corporation Resonant cavity field enhancing boundary
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
AR030019A1 (es) 1999-05-18 2003-08-13 Smithkline Beecham Corp Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US7943129B2 (en) 2000-05-26 2011-05-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
WO2001090190A2 (en) 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
KR20040076869A (ko) * 2001-12-18 2004-09-03 인노제네틱스 엔. 브이. 진단적 및 치료적 용도를 위한 정제된 ｃ형 간염 바이러스외피 단백질
EP1456237A2 (en) 2001-12-21 2004-09-15 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Method for cloning of variable domain sequences
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
WO2010081856A1 (en) 2009-01-14 2010-07-22 Ablynx Nv Pulmonary administration of immunoglobulin single variable domains and constructs thereof
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
ES2408582T3 (es) * 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US7070786B2 (en) * 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
AU2003264053A1 (en) 2003-08-12 2005-03-10 William M. Yarbrough Treatment for acne vulgaris and method of use
ATE554390T1 (de) 2003-08-20 2012-05-15 Ucb Pharma Sa Verfahren zur gewinnung von antikörpern
DK1737971T3 (da) * 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
EP1720908A2 (en) 2004-02-17 2006-11-15 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
KR101699142B1 (ko) * 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
US20050279676A1 (en) 2004-06-21 2005-12-22 Izzy Zuhair A Fluid filter assembly for a dispensing faucet
SI2311874T1 (sl) 2004-07-22 2017-12-29 Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics Vezavne molekule
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006034292A2 (en) * 2004-09-21 2006-03-30 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
WO2006040154A2 (en) 2004-10-14 2006-04-20 Dublin City University Prokaryotic two hybrid system
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
AU2005302453A1 (en) 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP1874824A4 (en) 2005-04-06 2009-12-30 Ibc Pharmaceuticals Inc METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF
CA2603940A1 (en) * 2005-04-08 2006-10-19 Nancy Ulbrandt Antibodies against mammalian metapneumovirus
EP2010568A1 (en) 2006-04-14 2009-01-07 Ablynx N.V. Dp-78-like nanobodies
WO2008000279A1 (en) 2006-06-26 2008-01-03 Aida Centre, S.L. Blister package integrating rfid based tags
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
US20100129354A1 (en) 2006-10-27 2010-05-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
CA2671581A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
WO2008077945A2 (en) * 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
EP2096121A1 (en) * 2008-02-29 2009-09-02 Institut Pasteur Of Shanghai Antiviral peptides comprising lipid attachment signals and methods of use
AU2009254501B2 (en) 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
ES2551854T3 (es) 2009-04-30 2015-11-24 Ablynx N.V. Procedimiento para la producción de anticuerpos de dominio
ES2643034T3 (es) * 2009-06-05 2017-11-21 Ablynx N.V. Construcciones de Nanobody contra el virus respiratorio sincicial humano (VRSH) trivalentes para la prevención y/o el tratamiento de infecciones de las vías respiratorias
WO2011064382A1 (en) * 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections

Also Published As

Publication number Publication date
HRP20182195T1 (hr) 2019-02-22
EP2285408A2 (en) 2011-02-23
JP5809557B2 (ja) 2015-11-11
WO2009147248A2 (en) 2009-12-10
EP2285408B1 (en) 2018-10-24
CA2726652A1 (en) 2009-12-10
AU2009254501B2 (en) 2014-07-31
CN102112155A (zh) 2011-06-29
AU2009254501A1 (en) 2009-12-10
US9193780B2 (en) 2015-11-24
US20160152693A1 (en) 2016-06-02
US20190077847A1 (en) 2019-03-14
EP3424526A1 (en) 2019-01-09
US10550174B2 (en) 2020-02-04
CY1121687T1 (el) 2020-07-31
PT2285408T (pt) 2019-02-01
SI2285408T1 (sl) 2019-02-28
ZA201009135B (en) 2012-06-27
JP2011521662A (ja) 2011-07-28
US9834595B2 (en) 2017-12-05
JP2015156867A (ja) 2015-09-03
DK2285408T3 (en) 2019-02-04
US20110182897A1 (en) 2011-07-28
HUE042053T2 (hu) 2019-06-28
ES2713864T3 (es) 2019-05-24
CN102112155B (zh) 2016-08-10
US20200123233A1 (en) 2020-04-23
WO2009147248A3 (en) 2010-07-15
PL2285408T3 (pl) 2019-05-31
US11518799B2 (en) 2022-12-06

Similar Documents

Publication Publication Date Title
ZA201009135B (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
IL251916A0 (en) Improved amino acid sequences directed against il-6r and polypeptides containing them for the treatment of il-6r-related diseases and disorders
AP2009005057A0 (en) Novel peptide inhibitors of hepatitis c virus replication
ZA201005331B (en) Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors
IL222997A0 (en) Soluble fragments of influenza virus pb2 protein capable of binding rna - cap
ZA201005913B (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
IL212184A (en) Conditional expression vector of protein (s) acting as immunomodulator (s), engineered training cells, their pharmaceutical composition and their use in drug preparation
ZA200808845B (en) Novel DNA sequences, vectors and proteins of Avian Influenza hemagglutinin
IL205238A0 (en) Directed evolution using proteins comprising unnatural amino acids
EP2091960A4 (en) PEPTIDE VACCINE AGAINST INFLUENZA VIRUS
IL197501A0 (en) Modifications of cupredoxin derived peptides and methods of use thereof
EP2234636A4 (en) FORMULATIONS OF STABILIZED PEPTIDES AND PROTEINS
PL2010572T3 (pl) Białka fuzyjne zawierające polipeptydy HPV i peptydy wzmagające odporność do leczenia i zapobiegania rakowi szyjki macicy
IL226771A0 (en) Recombinant elastase protein, the methods for its production and its use
IL243697A0 (en) Recombinant cc10 protein of human origin for the treatment of influenza
IL215316A (en) Medications containing tat hiv-derived amino acid sequences and their use in cancer treatment
ZA201200046B (en) Therapeutic peptides, polypeptides and nucleic acid sequences
EP2231622A4 (en) AMINO ACIDS AND OROTIC ACID CONTAINING PREPARATIONS
WO2006018431A3 (en) Peptides for the treatment of herpes virus infections
ZA200800566B (en) Therapeutic peptides and vaccines
IL201676A0 (en) Oral delivery of proteins and peptides
EG27024A (en) Natural or recombinant proteins for treatment and diagnosis of hepatitis C virus
GB0912155D0 (en) Therapeutic peptides, polypeptides and nucleic acid sequences
GB0921328D0 (en) Therapeutic peptides, polypeptides and nucleic acid sequences
HK1165808A (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders